Hoogendoorn Roel J, Wuisman Paul I, Smit Theo H, Everts Vincent E, Helder Marco N
Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, The Netherlands.
Spine (Phila Pa 1976). 2007 Aug 1;32(17):1816-25. doi: 10.1097/BRS.0b013e31811ebac5.
In 2 studies, the injection of chondroitinase ABC into intervertebral discs of mature goats was evaluated as an experimental disc degeneration model. The first study analyzed the development of degeneration in time; the second study determined the optimal enzyme concentration.
To develop reproducible, slowly progressive disc degeneration in a large animal model.
Currently available, small animal models of intervertebral disc degeneration have shortcomings in the comparability to humans in terms of size, geometry, and cell population. Also, the methods to induce degeneration in the current models do not mimic human degeneration, which starts with the loss of proteoglycans. Injecting the enzyme chondroitinase ABC into the nucleus pulposus mimics the loss of proteoglycans.
In Study 1, lumbar intervertebral discs of 17 goats were injected with chondroitinase ABC (0.25 U/mL) or phosphate-buffered saline. Degeneration was analyzed with radiograph analysis, MR imaging, and macroscopic and histologic scoring at 5 different time points (4, 8, 12, 18, and 26 weeks). Six control goats were analyzed. The second study used 6 goats in which 4 different concentrations of chondroitinase ABC (0.2-0.35 U/mL) or phosphate-buffered saline were injected. After 12 weeks, similar analyses as in Study 1 were performed.
After 12 weeks, degenerative signs were observed in all parameters in Study 1. The degeneration increased up to 18 weeks and leveled off after 26 weeks. The variability, however, was high. The second study showed a concentration dependent effect of chondroitinase ABC with all analyzed parameters. The injection of 0.25 U/mL chondroitinase ABC resulted in disc degeneration after 12 weeks without signs of severe degeneration.
Injection of chondroitinase ABC in the caprine intervertebral disc results in mild, slowly progressive disc degeneration. This effect was optimal at a concentration of 0.25 U/mL. This is a promising model of disc degeneration that deserves further study.
在两项研究中,评估了向成年山羊椎间盘内注射软骨素酶ABC作为一种实验性椎间盘退变模型。第一项研究分析了退变随时间的发展情况;第二项研究确定了最佳酶浓度。
在大型动物模型中建立可重复的、缓慢进展的椎间盘退变模型。
目前可用的小动物椎间盘退变模型在大小、几何形状和细胞数量方面与人类的可比性存在不足。此外,当前模型中诱导退变的方法并不能模拟始于蛋白聚糖丢失的人类退变过程。向髓核内注射软骨素酶ABC可模拟蛋白聚糖的丢失。
在研究1中,向17只山羊的腰椎间盘内注射软骨素酶ABC(0.25 U/mL)或磷酸盐缓冲盐水。在5个不同时间点(4、8、12、18和26周)通过X线片分析、磁共振成像以及宏观和组织学评分来分析退变情况。对6只对照山羊进行了分析。第二项研究使用了6只山羊,向其注射4种不同浓度的软骨素酶ABC(0.2 - 0.35 U/mL)或磷酸盐缓冲盐水。12周后,进行了与研究1中类似的分析。
在研究1中,12周后所有参数均观察到退变迹象。退变在18周时加剧,并在26周后趋于平稳。然而,变异性较高。第二项研究显示软骨素酶ABC对所有分析参数均有浓度依赖性效应。注射0.25 U/mL软骨素酶ABC在12周后导致椎间盘退变,但无严重退变迹象。
向山羊椎间盘内注射软骨素酶ABC可导致轻度、缓慢进展的椎间盘退变。在浓度为0.25 U/mL时这种效应最佳。这是一种有前景的椎间盘退变模型,值得进一步研究。